Cargando…
A novel modified RANKL variant can prevent osteoporosis by acting as a vaccine and an inhibitor
BACKGROUND: The discovery of receptor activator of nuclear factor‐ĸB ligand (RANKL) as the final effector in the pathogenesis of osteoporosis has led to a better understanding of bone remodeling. When RANKL binds to its receptor (RANK), osteoclastic differentiation and activation are initiated. Here...
Autores principales: | Ko, Young Jong, Sohn, Hong Moon, Jang, Yuria, Park, Mineon, Kim, Bora, Kim, Beomchang, Park, Jae‐Il, Hyun, Hoon, Jeong, Byeongseok, Hong, Chansik, Lim, Wonbong |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
John Wiley and Sons Inc.
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7967917/ https://www.ncbi.nlm.nih.gov/pubmed/33784004 http://dx.doi.org/10.1002/ctm2.368 |
Ejemplares similares
-
RANKL immunisation inhibits prostate cancer metastasis by modulating EMT through a RANKL-dependent pathway
por: Park, Mineon, et al.
Publicado: (2021) -
Inhibition of RANKL-Induced Osteoclastogenesis by Novel Mutant RANKL
por: Jang, Yuria, et al.
Publicado: (2021) -
Regulation of Osteosclerosis by Inoculated Cd133(+) PC3 Cells in Bone‐marrow Microenvironmental Niches
por: Kim, Donghwi, et al.
Publicado: (2019) -
Osteoporosis therapies and their mechanisms of action (Review)
por: Kim, Beomchang, et al.
Publicado: (2021) -
Effect of CD133 overexpression on bone metastasis in prostate cancer cell line LNCaP
por: Sohn, Hong Moon, et al.
Publicado: (2019)